Healio Minute

In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.

Read the full coverage here:

Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC

Global economic cost of cancer estimated to exceed $25 trillion over 30 years

Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints

Researchers develop AI model to accelerate radiation therapy planning for lung cancer

Asian, Black patients with lung cancer face longer wait times to radiation treatment

References:

Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826.

Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7.

Press Release

Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104

Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994.

In this edition, novel T-cell therapy effective against common viruses; FDA approves Brukinsa for chronic lymphocytic leukemia; meeting abstracts show inconsistent toxicity reporting and more. Read the full coverage here:

Novel T-cell therapy effective against common viruses after stem cell transplantation

FDA approves Brukinsa for chronic lymphocytic leukemia, small lymphocytic lymphoma

Review of meeting abstracts shows toxicity reporting inconsistent, incomplete

Cumulative anesthesia exposure linked to impaired neurocognitive function in pediatric ALL

Imetelstat confers durable transfusion independence in lower-risk myelodysplastic syndrome

References:

Alexander S, et al. Abstract 901. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Chin-Yee B, et al. Abstract 129. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2013; New Orleans.

Pfeiffer T, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2415.

Press Release

Press Release

In this edition, lobectomy alternatives show adverse event profiles; frequent CT scans not linked to better surgery outcomes; FDA approves adjuvant Keytruda, and more. Read the full coverage here:

Lobectomy alternatives show varying adverse event profiles in early-stage lung cancer

More frequent CT scans not linked to better outcomes after lung cancer surgery

Osimertinib-related pneumonitis incidence higher in real-world lung cancer population

FDA approves adjuvant Keytruda for non-small cell lung cancer

Tarlatamab active in recurrent small cell lung cancer

References:

Heiden BT, et al. J Natl Cancer Inst. 2023;doi:10.1093/jnci/djac208.

Paz-Ares L, et al. J Clin Oncol. 2023;doi:10.1200/JCO.22.02823.

Press Release

Sato Y, et al. CHEST. 2022;doi:10.1016/j.chest.2022.05.035.

Wang Q, et al. Ann Am Thorac Soc. 2022;doi:10.1513/AnnalsATS.202203-275OC.

In this edition, addition of tumor treating fields extends OS; atezolizumab-bevacizumab survival rates; screening leads to more stage I, less stage IV disease incidence, and more.

Read the full coverage here:

Addition of tumor treating fields to standard therapy extends OS in advanced lung cancer

Atezolizumab-bevacizumab confers 'much higher than usual' survival rates in NSCLC subset

Lung cancer screening leads to more stage I, less stage IV disease incidence

Anti-TIGIT regimens improve outcomes vs. anti-PD-1 alone in lung cancer subgroup

FDA approves adagrasib for certain adults with non-small cell lung cancer

References:

Johnson ML, et al. Abstract 397600. Presented at: ASCO Plenary Series: December 2022 Session; Dec. 20, 2022.

Press Release

Press Release

Provencio M, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5959.

Vachani A, et al. J Thorac Oncol. 2022;doi:10.1016/j.jtho.2022.08.011.

In this edition, groups support CMS policy update on colonoscopy; plant-based food intake and CRC research needed; FDA agrees on pediatric study to develop obefazimod and more.

Read the full coverage here:

Exact Sciences backs CMS policy update to waive cost-sharing for follow-up colonoscopy

Future research needed to investigate link between plant-based food intake, CRC

FDA agrees on Abivax's pediatric study plan to develop obefazimod for children with IBD

Roux-en-Y tied to increased risk for hospitalization related to alcohol-use disorder

Robotic liver resection for HCC reduced length of hospital stay, ICU admissions

References:

Benedetto FD, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.5697.

Kim J, et al. BMC Medicine. 2022;doi:10.1186/s12916-022-02633-7.

Mahmud N, et al. JAMA Surg. 2022;doi:10.1001/jamasurg.2022.6410.

Press Release

Press Release

In this edition, NCI director announces breast cancer diagnosis, neoadjuvant chemotherapy regimen in pancreatic cancer, gender harassment is in oncology and more.

Read the full coverage here:

NCI director announces breast cancer diagnosis, says prognosis 'very favorable'

Neoadjuvant chemotherapy regimen extends survival in pancreatic cancer

Survey shows gender harassment is 'strikingly common' in oncology

Proton pump inhibitor use linked to elevated cancer risk

Memorial Sloan Kettering pauses CAR-T clinical trial to investigate patient death

References:

Katz MHG, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.2319.

Press Release

Press Release

Subbiah IM, et al. J Clin Oncol. 2022;doi:10.1200/JCO.21.02574.

Tran TH, et al. Abstract 1843. Presented at: World Cancer Congress; Oct. 18-20, 2022; Geneva.

In this edition, cancer and COVID-19 increase risk for thromboembolism, glofitamab shows curative potential in lymphoma, efgartigimod improves platelet counts, and more.

Read the full coverage here:

Biomarkers predict thromboembolism risk, mortality among people with cancer, COVID-19

Glofitamab shows 'curative potential' in relapsed/refractory diffuse large B-cell lymphoma

Efgartigimod confers rapid improvement in platelet counts in immune thrombocytopenia

Odronextamab 'potentially curative' in third-line setting for follicular lymphoma

Dana-Farber professor receives William Dameshek Prize for multiple myeloma research

References:

Broome CM, et al. Abstract 3. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Hutchings M, et al. Abstract 441. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Khorana AA, et al. Abstract 136. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Kim TM, et al. Abstract 949. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

Press Release

In this edition, alcohol consumption increases cancer risk, medical marijuana associated with lower rates of opioid prescriptions, lifelong stress increases risk for cancer mortality, and more.

Read the full coverage here:

Many Americans unaware of alcohol links to cancer risk

Medical marijuana 'may be substituting for opioids for cancer-related pain'

Lifelong stress may increase risk for cancer mortality

FDA approves olutasidenib for certain adults with acute myeloid leukemia

Data support less aggressive approach before transplant in relapsed/refractory AML

References:

Bao Y, et al. JAMA Oncol. 2022;doi:10.1001/jamaoncol.2022.5623.

Moore JX, et al. SSM Popul Health. 2022;doi:10.1016/j.ssmph.2022.101185.

Press Release

Seidenberg AB, et al. Cancer Epidemiol Biomarkers Prev. 2022;doi:10.1158/1055-9965.EPI-22-0420.

Stelljes M, et al. Abstract 4. Presented at: ASH Annual Meeting and Exposition; Dec. 10-13, 2022; New Orleans.

In this episode, FDA grants fast track designation to REM-001; practice-changing treatment advances continue; proton partial breast radiotherapy appears effective and more.

Read the full coverage here:

FDA grants fast track designation to REM-001 for cutaneous metastatic breast cancer

Practice-changing treatment advances continue in early-stage triple-negative breast cancer

Proton partial breast radiotherapy appears effective, safe for early breast cancer

New endocrine therapy options for patients with breast cancer on the horizon, expert says

Use of contraception decreases after breast cancer diagnosis

References:

Choi JI, et al. Clin Transl Radiat Oncol. 2022;doi:10.1016/j.ctro.2022.08.013

Healio Interviews

Lambertini M, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetowrkopen.2022.33137.

Press Release

Traina TA, et al. Early-stage triple-negative breast cancer. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.

In this edition, fludarabine has been placed on the FDA's drug shortage list; epcoritamab is approved for advanced lymphoma; pembrolizumab with chemotherapy improves OS in gastric cancer, and more.

Read the full coverage here:

Fludarabine shortage requires flexibility, alternative approaches for CAR-T and HSCT

FDA grants priority review to epcoritamab for advanced lymphoma

Pembrolizumab regimen extends OS in metastatic gastric, gastroesophageal junction cancers

New endocrine therapy options for patients with breast cancer on the horizon, expert says

Treatment sequencing key as options increase for patients with urothelial cancer

References:

Petrylak DP. Sequencing therapy throughout the urothelial treatment continuum. Presented at: 40th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow; Nov. 9-11, 2022.

Press Release

Press Release